[MAYBANK] QoQ Cumulative Quarter Result on 30-Sep-2016 [#3]

Announcement Date
24-Nov-2016
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2016
Quarter
30-Sep-2016 [#3]
Profit Trend
QoQ- 69.42%
YoY- -15.46%
View:
Show?
Cumulative Result
30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 CAGR
Revenue 22,200,377 11,278,069 44,657,902 33,412,291 22,123,819 11,182,403 40,556,371 -33.10%
PBT 4,493,561 2,249,070 8,844,450 5,971,445 3,515,334 1,931,345 9,151,548 -37.78%
Tax -1,024,230 -503,966 -1,880,558 -1,457,626 -865,131 -480,444 -2,165,160 -39.31%
NP 3,469,331 1,745,104 6,963,892 4,513,819 2,650,203 1,450,901 6,986,388 -37.31%
-
NP to SH 3,361,237 1,702,797 6,742,992 4,382,394 2,586,692 1,426,751 6,835,939 -37.72%
-
Tax Rate 22.79% 22.41% 21.26% 24.41% 24.61% 24.88% 23.66% -
Total Cost 18,731,046 9,532,965 37,694,010 28,898,472 19,473,616 9,731,502 33,569,983 -32.24%
-
Net Worth 69,268,350 70,457,936 66,810,691 64,729,290 62,033,595 61,977,906 59,980,310 10.08%
Dividend
30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 CAGR
Div 2,358,403 - 5,168,567 1,971,830 1,958,873 - 5,124,818 -40.42%
Div Payout % 70.16% - 76.65% 44.99% 75.73% - 74.97% -
Equity
30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 CAGR
Net Worth 69,268,350 70,457,936 66,810,691 64,729,290 62,033,595 61,977,906 59,980,310 10.08%
NOSH 10,253,926 10,178,105 9,939,552 9,859,153 9,794,365 9,745,566 9,490,405 5.29%
Ratio Analysis
30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 CAGR
NP Margin 15.63% 15.47% 15.59% 13.51% 11.98% 12.97% 17.23% -
ROE 4.85% 2.42% 10.09% 6.77% 4.17% 2.30% 11.40% -
Per Share
30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 CAGR
RPS 216.51 110.81 449.29 338.90 225.88 114.74 427.34 -36.47%
EPS 32.78 16.73 67.84 44.45 26.41 14.64 72.03 -40.86%
DPS 23.00 0.00 52.00 20.00 20.00 0.00 54.00 -43.41%
NAPS 6.7553 6.9225 6.7217 6.5654 6.3336 6.3596 6.3201 4.54%
Adjusted Per Share Value based on latest NOSH - 9,992,777
30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 CAGR
RPS 184.02 93.48 370.17 276.95 183.38 92.69 336.17 -33.10%
EPS 27.86 14.11 55.89 36.33 21.44 11.83 56.66 -37.72%
DPS 19.55 0.00 42.84 16.34 16.24 0.00 42.48 -40.41%
NAPS 5.7416 5.8402 5.5379 5.3654 5.1419 5.1373 4.9717 10.08%
Price Multiplier on Financial Quarter End Date
30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 CAGR
Date 30/06/17 31/03/17 30/12/16 30/09/16 30/06/16 31/03/16 31/12/15 -
Price 9.63 8.92 8.20 7.50 8.14 9.02 8.40 -
P/RPS 4.45 8.05 1.83 2.21 3.60 7.86 1.97 72.24%
P/EPS 29.38 53.32 12.09 16.87 30.82 61.61 11.66 85.27%
EY 3.40 1.88 8.27 5.93 3.24 1.62 8.58 -46.08%
DY 2.39 0.00 6.34 2.67 2.46 0.00 6.43 -48.33%
P/NAPS 1.43 1.29 1.22 1.14 1.29 1.42 1.33 4.95%
Price Multiplier on Announcement Date
30/06/17 31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 CAGR
Date 30/08/17 25/05/17 23/02/17 24/11/16 25/08/16 27/05/16 25/02/16 -
Price 9.46 9.57 8.38 7.70 7.90 8.27 8.64 -
P/RPS 4.37 8.64 1.87 2.27 3.50 7.21 2.02 67.34%
P/EPS 28.86 57.20 12.35 17.32 29.91 56.49 12.00 79.60%
EY 3.47 1.75 8.10 5.77 3.34 1.77 8.34 -44.29%
DY 2.43 0.00 6.21 2.60 2.53 0.00 6.25 -46.76%
P/NAPS 1.40 1.38 1.25 1.17 1.25 1.30 1.37 1.45%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment